so, for example, there's a brilliant expert in france, professor jean-luc faye. he's at the university hospital in montpellier who was commissioned by the french medicines to look into the safety of these drugs for the french market. and so he started looking at what's called the preclinical literature, the research on animals first noticed something really disturbing, which is that these drugs when they're given to rats the active component, when it's given to rats, it makes them much more likely develop thyroid cancer. and we know these drugs work by changing by stimulating a hormone called glp one that i'm sure we'll talk about more. and we know you have receptors for glp one, not just your gut and in your brain, but in your thyroid. so kind of make sense of your screen with glp one, it might screw with the thyroid. so what he did is he looked at the data, but he did a big analysis of the databases in france and he compared diabetics who've been using drugs between i think it was 2006 and 2012 to diabetics who had not been using these drugs but what otherwise